The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 19, 2020 at 09:08 pm IST
Share
The Greater Cannabis Company, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced total revenue - ar was USD 0 compared to USD 2,620 a year ago. Operating loss was USD 70,925 compared to USD 78,439 a year ago. Net loss was USD 459,260 compared to USD 126,430 a year ago. For the nine months, total revenue was USD 48,044 compared to USD 2,620 a year ago. Operating loss was USD 240,925 compared to USD 330,593 a year ago. Net loss was USD 568,380 compared to USD 552,558 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.
THE GREATER CANNABIS COMPANY, INC. 
